Follicular Lymphoma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Follicular Lymphoma pipeline constitutes 7+ key companies continuously working towards developing 8+ Follicular Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Follicular Lymphoma Overview
Follicular lymphoma (FL) is typically a slow-growing or indolent form of non- Hodgkin lymphoma (NHL) that arises from B lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. Follicular lymphoma is usually not considered to be curable, but more of a chronic disease. Patients can live for many years with this form of lymphoma

"Follicular Lymphoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.

The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Follicular Lymphoma Pipeline Report: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years. Follicular Lymphoma Key players such as - InnoCare Pharma, Sound Biologics, Merck KGaA, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, MEI Pharma, Dr Reddy's Laboratories, Pharmacyclics, and others, are developing therapies for the Follicular Lymphoma treatment
• Follicular Lymphoma Emerging therapies such as - ICP 248, PSB 202, Avelumab, Abexinostat, Loncastuximab tesirine, Acalabrutinib, Zandelisib, DRL_RI, Ibrutinib, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.
• In June 2022, MEI Pharma and Kyowa Kirin reported new clinical data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
• In August 2021, MEI Pharma, Inc. initiated a trial titled " A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immuno chemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - The COASTAL Study"
• In November 2021, MEI Pharma, Inc. and Kyowa Kirin, announced that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma.

Route of Administration
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Follicular Lymphoma Pipeline Therapeutics Assessment
• Follicular Lymphoma Assessment by Product Type
• Follicular Lymphoma By Stage and Product Type
• Follicular Lymphoma Assessment by Route of Administration
• Follicular Lymphoma By Stage and Route of Administration
• Follicular Lymphoma Assessment by Molecule Type
• Follicular Lymphoma by Stage and Molecule Type

DelveInsight's Follicular Lymphoma Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Follicular Lymphoma Therapeutics Market include:
Key companies developing therapies for Follicular Lymphoma are - Incyte Corporation, Bristol Myers Squibb, Nordic Nanovector, ADC Therapeutics, MorphoSys, Nordic Nanovector, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharma, TG Therapeutics, Roche, Takeda, and several others

Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:
• ICP 248: InnoCare Pharma
• PSB 202: Sound Biologics
• Avelumab: Merck KGaA
• Abexinostat: Xynomic Pharmaceuticals
• Loncastuximab tesirine: ADC Therapeutics
• Acalabrutinib: AstraZeneca
• Zandelisib: MEI Pharma
• DRL_RI: Dr Reddy's Laboratories
• Ibrutinib: Pharmacyclics


Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Follicular Lymphoma Pipeline Analysis:
The Follicular Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
• Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies at:
https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Follicular Lymphoma Pipeline Market Drivers
• Increase in prevalence of Follicular Lymphoma
• Emergence of effective novel therapies

Follicular Lymphoma Pipeline Market Barriers
• Lack Of Cost-Effective Treatment6

Scope of Follicular Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key Follicular Lymphoma Companies: InnoCare Pharma, Sound Biologics, Merck KGaA, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, MEI Pharma, Dr Reddy's Laboratories, Pharmacyclics, and others
• Key Follicular Lymphoma Therapies: ICP 248, PSB 202, Avelumab, Abexinostat, Loncastuximab tesirine, Acalabrutinib, Zandelisib, DRL_RI, Ibrutinib, and others
• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers

Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Follicular Lymphoma Report Introduction
2 Follicular Lymphoma Executive Summary
3 Follicular Lymphoma Overview
4 Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment
5 Follicular Lymphoma Pipeline Therapeutics
6 Follicular Lymphoma Late Stage Products (Phase II/III)
7 Follicular Lymphoma Mid Stage Products (Phase II)
8 Follicular Lymphoma Early Stage Products (Phase I)
9 Follicular Lymphoma Preclinical Stage Products
10 Follicular Lymphoma Therapeutics Assessment
11 Follicular Lymphoma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Follicular Lymphoma Key Companies
14 Follicular Lymphoma Key Products
15 Follicular Lymphoma Unmet Needs
16 Follicular Lymphoma Market Drivers and Barriers
17 Follicular Lymphoma Future Perspectives and Conclusion
18 Follicular Lymphoma Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies- https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Follicular Lymphoma Market https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Follicular Lymphoma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Follicular Lymphoma Epidemiology https://www.delveinsight.com/report-store/follicular-lymphoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Follicular Lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.